Literature DB >> 18215454

Disruption of FAK signaling: a side mechanism in cytotoxicity.

Nikolaos A Chatzizacharias1, Gregory P Kouraklis, Stamatios E Theocharis.   

Abstract

Focal adhesion kinase (FAK) is a non-receptor protein tyrosine kinase (PTK) which acts as an early modulator in the integrin signaling cascade. FAK phosphorylation and its consequent activation regulate several basic biological cellular functions. On the contrary, dysregulation of FAK signaling is implicated in the malignant transformation of cells, as well as in nonmalignant pathological conditions. With respect to cytotoxicity, accumulating data indicate that FAK participates in the mechanism of action of the known cytotoxic reactive oxygen species (ROS). Additionally, evidence was presented that different cytotoxic substances, such as arsenic (As), lead (Pb), acrylamide, methylisothiazolinone (MIT), dichlorovinylcysteine (DCVC) and halothane, acted, at least in part, by downregulating FAK tyrosine phosphorylation, while the bacterial toxins Pasteurella multocida toxin and Escherichia coli cytotoxic necrotizing factor, have been shown to exert cytotoxic effects by inducing FAK tyrosine phosphorylation. The observation that upregulation as well as downregulation of FAK activity both result in cytotoxic effects seems contradictory. Even though a common mode of action, with respect to the dysregulation of FAK signaling, for these cytotoxic substances has not yet been discovered, a cumulative approach could be established by focusing on FAK activation and signaling cascade. According to these data, interfering with FAK signaling might be of a potential use in blocking these cytotoxic effects. Further studies are needed on the possible implication of FAK in substance-induced cytotoxicity, as well as the possibility that such effects might be hindered or even blocked by restoring FAK signaling.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18215454     DOI: 10.1016/j.tox.2007.12.003

Source DB:  PubMed          Journal:  Toxicology        ISSN: 0300-483X            Impact factor:   4.221


  7 in total

1.  Evaluation of FAK and Src expression in human benign and malignant thyroid lesions.

Authors:  Christina Michailidi; Costas Giaginis; Vassilios Stolakis; Paraskevi Alexandrou; Jerzy Klijanienko; Ioanna Delladetsima; Nicolaos Chatzizacharias; Gerasimos Tsourouflis; Stamatios Theocharis
Journal:  Pathol Oncol Res       Date:  2010-04-20       Impact factor: 3.201

2.  Expression and clinical significance of focal adhesion kinase in the two distinct histological types, intestinal and diffuse, of human gastric adenocarcinoma.

Authors:  Constantinos T Giaginis; Stephanie Vgenopoulou; Gerasimos S Tsourouflis; Ekaterini N Politi; Gregorios P Kouraklis; Stamatios E Theocharis
Journal:  Pathol Oncol Res       Date:  2008-11-06       Impact factor: 3.201

3.  Myelin activates FAK/Akt/NF-kappaB pathways and provokes CR3-dependent inflammatory response in murine system.

Authors:  Xin Sun; Xi Wang; Tianxiang Chen; Tianyi Li; Kai Cao; Andrew Lu; Yongxiong Chen; Dongming Sun; Jianhong Luo; Jianqing Fan; Wise Young; Yi Ren
Journal:  PLoS One       Date:  2010-02-23       Impact factor: 3.240

Review 4.  Mechanical regulation of signaling pathways in bone.

Authors:  William R Thompson; Clinton T Rubin; Janet Rubin
Journal:  Gene       Date:  2012-05-02       Impact factor: 3.688

Review 5.  The molecular basis of bone mechanotransduction.

Authors:  M P Yavropoulou; J G Yovos
Journal:  J Musculoskelet Neuronal Interact       Date:  2016-09-07       Impact factor: 2.041

6.  Living biointerfaces based on non-pathogenic bacteria to direct cell differentiation.

Authors:  Aleixandre Rodrigo-Navarro; Patricia Rico; Anas Saadeddin; Andres J Garcia; Manuel Salmeron-Sanchez
Journal:  Sci Rep       Date:  2014-07-28       Impact factor: 4.379

7.  Two combined photosensitizers: a goal for more effective photodynamic therapy of cancer.

Authors:  P Acedo; J C Stockert; M Cañete; A Villanueva
Journal:  Cell Death Dis       Date:  2014-03-13       Impact factor: 8.469

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.